🇺🇸 FDA
Patent

US 11638704

Bicyclic compounds and their use in the treatment of cancer

granted A61KA61K31/404A61K31/41

Quick answer

US patent 11638704 (Bicyclic compounds and their use in the treatment of cancer) held by TEMPEST THERAPEUTICS, INC. expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEMPEST THERAPEUTICS, INC.
Grant date
Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/404, A61K31/41, A61K31/416, A61K31/4184